



Inpatient

UPDATE: New HCPCS Code to be Used When Billing for Axicabtagene Ciloleucel (brand name YESCARTA™)



UPDATE: New HCPCS Code to be Used When Billing for Axicabtagene Ciloleucel (brand name YESCARTA™)

Effective April 1, 2018, hospital claims for Axicabtagene Ciloleucel (brand name YESCARTA™) should be billed using HCPCS code Q2041. Hospitals submitting claims for YESCARTA™ for the period December 1, 2017 through March 31, 2018 should bill using HCPCS code J3590, unlisted biologic.

New York State Medicaid covers YESCARTA™ for members 18 years of age and older, who have a diagnosis of B-cell lymphoma, when specific criteria are met. Coverage criteria and billing guidelines are outlined in the January 2018 Medicaid Update.

Contact Details:
1-800-343-9000
emednyalert@csra.com

If you are having problems viewing content within this newsletter, please email emednyalert@csra.com for further assistance

The Department has attempted to ensure that the information contained in these notifications is as accurate as possible. However, no e-mail transmittals or materials provided are intended to constitute legal or medical advice.